Background/Aim: PTP1B tyrosine phosphatase is involved in the development of many types of cancers, such as breast cancer or lung cancer. Therefore, PTP1B is a promising target for anticancer therapy. The purpose of this review was to present the studies on selected PTP1B inhibitors as a possible treatment and describe the latest trends of current research in this field. Materials and Methods: This literature review was performed using the PubMed database and the analysis of previous research studies of our Department. Results: Recent studies have shown that PTP1B, due to its implication in oncogenic transformation, represents a promising drug target. Conclusion: The selected compounds that are effective PTP1B inhibitors can be considered a promising anticancer treatment, both as monotherapy and in combination with other anticancer drugs.
PTP1B Activates Oncogenic Src KinasesPTP1B contributes to oncogenic properties through activation of non-receptor tyrosine kinase Src, which is deregulated in multiple tumor types (11). The crucial role of Src kinases in tumor development is due to their effect on proliferation, survival, adhesion, migration, invasion and metastasis. Src kinase activity has been reported to be elevated in many human cancer cell lines, e.g. breast cancer, lung cancer and 3379